Drugs / iPSC-MNP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06765564 | Mar 2024 → Mar 2025 overdue | amyotrophic lateral sclerosis | Shanghai East Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iPSC-MNP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06765564 ↗ |
| Action | Restore | “can replace damaged motor neurons, and restore motor conduction function” NCT06765564 ↗ |
| Modality | Cell therapy | “human iPSC-derived motor neuron precursor cells” NCT06765564 ↗ |
| Route | Subcutaneous | “through the subcutaneous drug pouch” NCT06765564 ↗ |